1/1
Cost–effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma. Supplementary figures and table.
figure
posted on 2023-07-04, 07:27 authored by Zhiwei Zheng, Ling Fang, Hongfu Cai, Huide ZhuSupplementary figures 1-5 and Supplementary table 1.
